EGFR and non-small cell lung carcinoma: In a retrospective study evaluating NSCLC patients from the IMMUNOTARGET registry, the response of 125 pre-treated EGFR-mutated patients with ICI monotherapy was compared among patients with different EGFR mutation subgroups (69).